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Background: LKB1, also known as STK11, is a master kinase that serves as an energy metabolic sensor and is
involved in cell polarity regulation. Recent studies have indicated that LKB1 is related to breast tumorigenesis
and breast cancer progression. However, little work has been done on the roles of LKB1 in cell polarity and
epithelial-mesenchymal transition in breast cancer. In this study, we tried to prove that loss of LKB1 disrupts
breast epithelial cell polarity and causes tumor metastasis and invasion.
Methods: The relationships of LKB1 expression to clinic-pathological parameters and epithelial markers E-cadherin
and high-molecular-weight -cytokeratin (HMW-CK) were investigated in 80 clinical breast cancer tissue samples and
their paired normal control breast tissue samples by using immunohistochemistry. Then, the LKB1 expressions in
metastatic and non-metastatic breast cancer cell lines were compared. The roles of LKB1 in cell polarity and
epithelial-mesenchymal transition in breast cancer were determined by using immunofluorescence, western blot
assay, and cell migration and invasive assays. Finally, the non-transformed human breast cell line MCF-10A was
cultured in three dimensions to further reveal the role of LKB1 in breast epithelial cell polarity maintenance.
Results: Histopathological analysis showed that LKB1 expression level was significantly negatively correlated
with breast cancer TNM stage, and positively correlated with ER/PR status and expression levels of E-cadherin
and HMW-CK. Immunofluorescence staining showed that LKB1 was co-localized with E-cadherin at adheren
junctions. In vitro analysis revealed that loss of LKB1 expression enhanced migration, invasion and the acquisition of
mesenchymal phenotype, while LKB1 overexpression in MDA-MB-435 s cells, which have a low basal level of LKB1
expression, promoted the acquisition of epithelial phenotype. Finally, it was found for the first time that endogenous
LKB1 knockdown resulted in abnormal cell polarity in acini formed by non-transformed breast epithelial cells grown in
3D culture.
Conclusion: Our data indicated that low expression of LKB1 was significantly associated with established markers of
unfavorable breast cancer prognosis, such as loss of ER/PR, E-cadherin and HMW-CK. Knockdown of endogenous LKB1
gave rise to dysregulation of cell polarity and invasive phenotype of breast cancer cells.
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The tumor suppressor gene LKB1, also known as serine/
threonine protein kinase 11 (STK11), encodes a serine/
threonine protein kinase that has multiple cellular func-
tions, including tumor suppression, cell cycle regulation,
and promotion of apoptosis. Germ line mutations of
LKB1 give rise to Peutz-Jeghers Syndrome (PJS), a rare
cancer susceptibility syndrome characterized by predis-
position to gastrointestinal polyposis, mucocutaneous
melanin pigmentation and multi-organ cancer suscepti-
bility [1,2]. LKB1 serves as a master kinase responsible
for phosphorylation of the conserved threonine in the
catalytic domains of 14 AMPK-related protein kinases
(AMPKα1, AMPKα2, BRSK1, BRSK2, NUAK1, NUAK2,
QIK, QSK, SIK, MARK1, MARK2, MARK3, MARK4
and MELK) [3-6]. AMPK is the most important down-
stream target of LKB1 and functions as a cellular energy
sensor. Phosphorylation of AMPK will activate TSC1/
TSC2, suppress the mTOR activity and dephosphorylate
mTOR effectors S6K and 4E-BP1, which are involved in
regulation of protein translation initiation [4,7]. Thus,
LKB1 regulates multiple biological pathways involved in
cell growth and metabolism.
LKB1 also plays crucial roles in establishment and
maintenance of cell polarity. Par4, a homologue of hu-
man LKB1, has been found to control Caenorhabditis
elegans embryonic polarity by regulating activities of
anillin family scaffold proteins [8,9]. Mutations in Par4
result in lack of germline determinant segregation, syn-
chrony of the second embryonic division and embryonic
lethality [9,10]. Dlkb1, another homologue of LKB1 in
Drosophila melanogaster, is required for early anterior-
posterior polarity and apical-basal polarity. Cells with
dlkb1 mutation show asymmetric division and abnormal
spindle formation [11]. Furthermore, LKB1 helps
establish and maintain cell polarity in mammals. It
has been reported that loss of Lkb1 allele impairs
corticofugal axon extension in telencephalic neuronal
progenitors, resulting in cortical thinning and agenesis
of the corpus callosum in mice. This abnormal pheno-
type has been traced to a defect in activation of Brsk/
Sad kinases, which appear to be responsible for cyto-
skeletal reorganization through tau phosphorylation
[12,13]. SAD/MAPK (Par-1) kinases are other down-
stream targets of LKB1 and mainly expressed in the
brain. LKB1 regulates the formation of axon/dendrite
polarity by activating SAD/MAPK (Par-1) kinases
[9,14]. LKB1 also plays a critical role in maintenance of
mammalian epithelial cell polarity. Research has shown
that LKB1 can promote the formation of apical brush
borders and the transport of basolateral membrane
proteins in Madin Darby canine kidney (MDCK) cells
[15,16]. In addition, LKB1 can act as an upstream
regulator of Par family members and increase theiractivities in epithelial cells of invertebrates similar to
Drosophila and C. elegans [15,17,18]. In brief, LKB1 is
an important regulator of cell polarity.
Loss of cell polarity is one of hallmarks for epithelial-
mesenchymal transition (EMT) and cancer progression
[19,20]. Based on the above research, we hypothesized
that loss of LKB1 may disrupt the breast epithelial cell
polarity and cause tumor progression and invasion.
Zhuang et al. [21] have demonstrated that overexpres-
sion of LKB1 protein reduces breast cancer microvessel
density and inhibits metastasis. In the present study, our
data first revealed that LKB1 expression level was signifi-
cantly negatively correlated with human breast cancer
TNM stage, and positively correlated with expression
levels of E-cadherin and high molecular weight cytokera-
tin (HMW-CK) in clinical breast cancer tissue samples.
In addition, the three dimensional (3D) culture system
of non-transformed breast epithelial cells was used for
the first time to show that loss of LKB1 disrupted the
cell polarity in acini and promoted the EMT progression
in breast cancer migration and metastasis.Materials and methods
Patients and tissue samples
With approval by the institutional review board (IRB), a
total of 80 breast cancer tissue samples and their paired
normal control tissue samples were obtained from the
First Affiliated Hospital of Xi’an Jiaotong University
College of Medicine and the National Engineering
Center for Biochip (Shanghai, China). Clinical tumor
stages were defined as stagesI, II and III according to
tumor-node-metastasis (TNM) classification system. Clini-
copathological characteristics of these patients from whom
these tissues were obtained were presented in Table 1.Antibodies and reagents
Antibodies used in this study included anti-LKB1 (SC-
32245/CST#3050), anti-E-cadherin (BD-610405), anti-
α-SMA (sigma-A2547), anti-N-cadherin (BD-610920),
and anti-GM130 (BD-610822). Lipofectaminet™ 2000
(Invitrogen) was used for siRNA transfection.Vector and siRNA
LKB1 overexpression vector was a gift from Professor
Zhijun Luo, Department of Biochemisty, Boston University
School of Medicine, Boston, MA, USA. LKB1 siRNA was
purchased from Invitrogen. The LKB1 siRNA sequences
were as follows: LKB1-1342 sense: 5'CCG UCAAGAUC
CUCAAGAAT 3'; antisense: 5'UUCUUGAGGAUCUUG
ACGGTT3' and LKB1-1972 sense: 5'AAAGGGAUGCU
UGAGUACG TT 3'; antisense: 5'CGUACUCAAGCA
UCCCUUUTT 3'.
Table 1 Clinical profile of breast cancer patients
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Non-transformed breast epithelial cell line MCF-10A was
obtained from ATCC (VA, USA). MCF-10A cells were
cultured in DMEM/F12 (Hyclone) supplemented with 5%
horse serum (Hyclone), 1% penicillin/streptomycin, 0.5 μg/
ml hydrocortisone (Sigma, H-0888), 10 μg/ml insulin
(Sigma, I-1882) and 20 ng/ml recombinant human EGF
(Peprotech, 100–15). Breast cancer cell lines MCF-7, T47D,
SKBR3, and MDA-MB-435 s were cultured in DMEM
(Hyclone) supplemented with 10% FBS (Hyclone). BT474
were cultured in RPMI-1640 medium (Hyclone) supple-
mented with 10% FBS (Hyclone). All cell cultures were
maintained at 37°C in a humidified atmosphere containing
5% CO2.
Immunohistochemistry
Fixed tumor tissue samples were sectioned (5 μm), deparaf-
finized, rehydrated, and subjected to heat-induced antigen
retrieval in EDTA Buffer (1.0 mM, pH 8.0) for 10 min in a
microwave oven. Nonspecific binding sites were blocked
with 10% goat serum in PBS for 30 min, and antibodyagainst LKB1 (1:50 dilution) (SC-32245) were applied
overnight at 4°C, followed by second antibodyavidin-
biotin-peroxidase conjugated anti-mouse IgG (SP-9000,
ZSGB-BIO 1:200 dilution) for 30 min at room temperature
(RT). Proteins were visualized using 3,3′-diaminobenzidine
(DAB) as the substrate.
Immunohistochemical evaluation and statistical analysis
Imaging of immunohistochemistry (IHC) was performed
using a section microscope scanner (leica MP, SCN400).
The expression level of LKB1 was assessed as the
percentage of the tumor cells with positive staining. The
staining intensity was rated as 0 (negative), 1 (weakly
positive), 2 (moderately positive), or 3 (strongly positive).
Estrogen receptor/progesterone receptor (ER/PR) status
was defined as low (ER/PR 0-2+), moderate (ER/PR 3-4+),
and high (ER/PR 5-6+), where the numerals 0–6 indicated
the total number of ER and PR positive symbols +. The
relationships of LKB1 expression to clinico-pathological
characteristics and other genes were analyzed using t-test
and Fisher’s exact test. P < 0.05 was considered statistically
significant.
Western blot assay
Cells were lysed with RIPA buffer supplemented with
protease inhibitors (Roche, NJ, USA), PMSF and phos-
photase inhibitors. Protein lysates were subjected to
10% SDS-PAGE, transferred to nitrocellulose mem-
branes (Bio-Rad, CA, USA), and incubated with the
indicated antibody. The reactive bands were developed
by chemiluminescence with the luminol reagent (SC-
2048). The blots were re-probed with GADPH anti-
body as a loading control.
Immunofluorescence
MCF-7 cells were cultured on chamber slides in DMEM
(Hyclone) supplemented with 10% FBS, fixed with 4%
paraformaldehyde solution for 10 min at RT, washed
three time with PBST and then permeabilized with 0.1%
Trition X-100 for 10 min. The slides were blocked with
5% BSA and 10% horse serum in PBST for 1 h at RT
and incubated with antibodies against LKB1 (1:200)
(CST#3050) at 4°C overnight. After being rinsed with
PBST three times, cells were incubated with secondary
antibody Alexa Fluor 633 (Invitrogen #A21063) (1:200)
for 1 h at RT. After being washed twice, cells were
stained with 5 μg/ml DAPI, followed by imaging with
con-focal microscopy (Leica SP5II).
Wound healing assay
Cells were seeded in 6-well plates and cultured with
DMEM containing 10% FBS until cells reached sub-
confluence. After removal of the culture medium, a
monolayer of the sub-confluent cells was scratched
Figure 1 (See legend on next page.)
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Figure 1 LKB1 immunohistochemistry staining in normal mammary and breast cancer tissues. Low-power (scale bar, 150 μm) and high-power
(scale bar, 50 μm) photomicrographs showed (A) LKB1 localization in the cytoplasm of normal luminal epithelial cells, (B) strong LKB1 immunostaining in
stageIbreast cancer tissues, (C) moderately positive LKB1 staining in stage IIbreast cancer tissues, (D) weakly positive LKB1 staining in stage III breast cancer
tissues, (E) strong LKB1 immunostaining in ER/PR+++ breast cancer tissues, (F) weakly positive LKB1 immunostaining in ER/PR + breast cancer tissues,
(G) strong LKB1 immunostaining in E-cadherin+++ breast cancer tissues, (H) negative LKB1 staining in E-cadherin breast cancer tissues, (I) strong LKB1
immunostaining in HMW-CK+++ breast cancer tissues, and (J) negative LKB1staining in HMW-CK breast cancer tissues.
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wounded monolayer were washed with PBS twice and
cultured in FBS-free medium for 48 h. Cell migration
into the wound area was monitored by inverted mi-
croscopy, photographed at the indicated time points,
and analyzed using Leica LAS EZ software. The migra-
tion distance (distance of cell migration, mm) was cal-
culated by subtracting the distance measured between
the edges of the lesion at 48 h from the distance mea-
sured at 0 h.Cell invasion assay
Cell invasion experiments were performed using the
Bio-Coat cell migration chamber (BD Biosciences, MA,
USA), which consists of a 24-well companion plate with
cell culture inserts containing a filter with 8 μm-diameter
pores. Filters were coated with basement membrane growth
factor-reduced matrigel™ (BD Biosciences, Cat#354230).
Cells re-suspended in DMEM/BSA medium (3 × 105 cells/
500 μl) were added to the insert (upper chamber) and
DMEM containing 20% FBS was placed in the lower cham-
ber (500 μl per well). After incubation at 37°C for 48 h,
non-invading cells were removed from the upper surface of
the membrane with a cotton-tipped applicator while
invading cells on the lower surface were fixed with 4%
paraformaldehyde fixative and stained with crystal
violet. Cells from 5 randomly chosen microscopic
fields were counted and cell invasion was expressed as
the number of cells per mm2.Three-dimensional cell culture
100 μl growth factor-reduced matrigel™ (BD Biosciences,
#354230) was added to each well of a 4-well chamber
slide (Nunc, Rochester, NY,177437) and incubated in
a cell culture incubator for 20 min to solidify. Cells
were trypsinized and re-suspended in the assay medium
DMEM/F12 (5% horse serum, 0.5 μg/ml hydrocortisone,
10 μg/ml insulin, and 1% penicillin/streptomycin) sup-
plemented with 2.5% matrigel and 5 ng/ml EGF. 1 ml of
the cell suspension was added into the pre-coated cham-
ber slide to generate 5000 cells/well. The chamber slide
was transferred into a cell culture incubator and the
assay medium (2.5% matrigel and 5 ng/ml EGF) was
replaced every 4 days.Results
LKB1 expression level was significantly negatively
correlated with breast cancer stage and positively
correlated with ER/PR status
LKB1 expression levels in normal mammary and breast
cancer tissues were determined by immunohistochemis-
try. Normal mammary tissues showed uniform and
strong cytoplasmic staining of LKB1, when compared
with breast cancer tissues (Figure 1A). Statistically signifi-
cant LKB1 down-regulations were detected in different
stages (TNM) of breast cancer (Table 2) (Figure 1B,C,D)
(Figure 2A). Moderately strong staining was observed in
69% (11 cases) of stageIbreast cancer. Forty-five percent (17
cases) of stageII breast cancer showed moderately strong
LKB1 staining while 51% (19 cases) had weak staining. Four
(19%) out of 21 stage III breast cancer cases were “com-
pletely negative” for LKB1 staining. In summary, stageII
cases demonstrated reduced levels of LKB1 staining, when
compared with stageIcases (p = 0.0021), and stage III cases
showed loss or reduced levels of LKB1 staining, when
compared with stageIcases (p = 0.0006).
Interestingly, a significant correlation was found between
LKB1 expression and ER/PR status in breast cancer. ER/PR
positive breast cancer had an LKB1 expression level several
times higher than that of ER/PR negative breast cancer
(Figure 1E and F) (Figure 2B). Breast cancer cases with low
or moderate ER/PR status showed reduced levels of LKB1
staining, when compared with high ER/PR cases (p = 0.018)
(p = 0.0007). Eighty percent (20 cases) of breast cancer
cases having high ER/PR status were moderately stained for
LKB1, in contrast to 55% (20 cases) of moderate ER/PR
cases and 42% (5 cases) of low ER/PR cases.
LKB1 expression level was positively correlated with
expression levels of E-cadherin and HMW-CK in clinical
breast cancer tissues
E-cadherin is an important cancer metastasis suppressor
and is required for cell-cell adhesion in the epithelial
tissue [22]. High-molecular-weight keratins (HMW-CK)
include CK1, CK5, CK10 and CK14, which can be recog-
nized by monoclonal antibody 34β12 we used in this
study. Among these cytokeratins, CK5 and CK14 are
two widely used markers for the basal epithelial pheno-
type and for the basal-like breast cancer, which is often
associated with poor prognosis and invasion phenotype
[23]. Therefore, we investigated the relationships of
Table 2 Association of LKB1 immunoreactivity with human breast tumor stage
Clincal stage Negative <25% Weak 25%-50% Moderate 50%-75% Strong >75% Score P value
Stage I 5(31) 8(50) 3(19) 30 —
Stage II 1(3) 19(51) 13(36) 4(10) 57 0.0021
Stage III 4(19) 6(29) 9(42) 2(10) 30 0.0006
Fisher’s exact test was performed to determine the association of LKB1 immunoreactivity with stage I, stage II or stage III breast cancer.
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cancer tissues, hoping to reveal the role of LKB1 in
breast cancer progression.
Here, expression levels of E-cadherin were categorized
as low (−/+) and high (++/+++). Expression levels of
HMW-CK were categorized as negative (−), low (+) and
high (++/+++). Significant positive correlations were
detected for the first time between LKB1 intensity and
metastasis suppressor E-cadherin and between LKB1 in-
tensity and basal-like breast cancer marker HMW-CK.
As shown in Table 3, 71% (22 cases) of breast carcin-
omas having low E-cadherin expressions showed nega-
tive or weak staining for LKB1, in contrast to 36% (10
cases) of the high expression cases (Figure 1G and H)
(Figure 2C). Fifty-eight percent (7 cases) of breast car-
cinomas with low HMW-CK expressions showed weak
staining for LKB1, and 64% (7 cases) negative HMW-CK
samples showed negtive or weak staining for LKB1, as
compared to 38% (6 cases) of the high HMW-CK ex-
pression cases (Figure 1I and J) (Figure 2D), indicatingFigure 2 The relationship of LKB1 expression level with cancer stage,
cases showing the relationship of LKB1 expression level with cancer stage
and with HMW-CK expression (D).that LKB1 expression level was positively correlated with
the expression level of HMW-CK in clinical breast
cancer tissues (Figure 1I and J) (Figure 2D).
LKB1 expression level was decreased in metastatic breast
cancer cell lines
To further determine whether LKB1 expression is asso-
ciated with metastatic progression of breast cancer, we
examined the expression levels of LKB1 in immortalized
breast epithelial cell line MCF-10A and breast cancer
cell lines, including luminal A subtype (MCF-7 and
T47D), luminal B subtype BT474, and metastatic SKBR3
and MDA-MB-435 s. As shown in Figure 3, LKB1 pro-
tein levels were decreased in metastatic breast cancer
cell lines. The expression levels of LKB1 in immortalized
and luminal A/B subtypes were much higher than those
in the metastatic cells. For instance, the LKB1 protein
level in MCF-7 was approximately 3-fold higher than
that in MDA-MB-435 s. This result further proved our
speculation that LKB1 was involved in regulation ofER/PR status and HMW-CK expression. Distribution of breast cancer
(stage I/stage II/stage III) (A), with (B), with E-cadherin expression (C),
Table 3 Association of LKB1 immunoreactivity with clinicopathologic features of human breast cancer
Clincal Stage Negative <25% Weak 25%-50% Moderate 50%-75% Strong >75% Score P value
ER/PR(6–5) 20(80) 5(20) 40 —
ER/PR(4–3) 1(3) 12(39) 17(55) 1(3) 49 0.018
ER/PR (2–0) 1(8) 6(50) 5(42) 16 0.0007
E-cadherin(++/+++) 10(36) 16(57) 2(7) 48 —
E-cadherin(+/−) 2(6) 20(65) 9(29) 38 0.0003
HMW-CK(++/+++) 6(38) 7(44) 3(18) 29 —
HMW-CK(+) 7(58) 5(42) 17 0.0003
HMW-CK(−) 1(9) 6(55) 4(36) 14 < 0.0001
Fisher’s exact test was performed to determine the association of LKB1 immunoreactivity with ER/PR, her2, E-cadherin or HMW-CK.
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and MDA-MB-435 s cell lines were chosen to test the
roles of LKB1 in breast cancer migration and invasion in
the following experiments.
LKB1 regulated breast cancer cell migration and invasion
LKB1 was knocked down in LKB1-expressing MCF-7
cells by small interfering RNA (siRNA) to gain insight
into the roles of LKB1 in breast cancer metastasis. The
migration and invasion of LKB1 knock-down cells wereFigure 3 LKB1 expressions in different breast cancer cell lines.
(A) LKB1 expressions in immortalized breast epithelial cell line MCF-10A,
luminal A subtype (MCF-7, BT474 and T47D) and metastatic SKBR3 and
MDA-MB-435 s. (B) LKB1 expressions were quantified using scanning
densitometry and LKB1 expressions in breast cancer cells were
calculated as ratios to the LKB1 expression in immortalized breast
epithelial cell line MCF-10A.assessed with monolayer wound healing assay and inva-
sion assay. As shown in Figure 4, LKB1 knock-down
MCF-7 cells showed an approximately 2-fold increase in
migration and a 3-fold increase in invasion, compared
with LKB1-expressing MCF-7 cells, indicating that LKB1
knockdown significantly induced the migration and
invasion of MCF-7 cells.
Our results indicated that LKB1 suppressed the migra-
tion and invasion of breast cancer cells in vitro. This
finding inspired us to speculate on the underlying mech-
anisms for regulation of invasion and metastasis by
LKB1. LKB1 is an important regulator of cell polarity
and is involved in regulation of epithelial-mesenchymal
transition (EMT) [24], while EMT is a biologic process
that allows epithelial cells to lose their cell polarity and
cell-cell adhesion and to gain migratory and invasive
properties [25-28]. Thus we examined whether LKB1
suppressed migration and invasion of breast cancer cells
by regulating EMT and cell polarity in the following
section.
Loss of LKB1 up-regulated N-cadherin and α-SMA but
down- regulated E-cadherin
To investigate the function of LKB1 in regulation of cell
polarity and EMT process, we first examined its location
in breast epithelial cells. Immunofluorescence staining
showed that endogenous LKB1 was localized at cell-cell
junctions of MCF-10A cells. Z axis projections showed
that LKB1 was mainly co-localized with E-cadherin at
adheren junctions (Figure 5A). After that, we examined
the expressions of epithelial marker E-cadherin and
mesenchymal markers N-cadherin and α-SMA in LKB1
knock-down MCF-7 cells and LKB1 over-expressing
MDA-MB-435 s cells. LKB1 over-expression induced
strong up-regulation of E-cadherin and significant
down-regulation of N-cadherin and α-SMA (Figure 5B).
On the other hand, N-cadherin and α-SMA were up-
regulated while E-cadherin was down-regulated in LKB1
knock-down cells (Figure 5C). LKB1 knock-down in-
duced down-regulation of E-cadherin in mRNA and
protein levels (Figure 6).
Figure 4 LKB1 affected migration and invasion of breast cancer cell lines. (A) LKB1 protein levels in control non-targeting siRNA (NT) and
siLKB1 1342/1972 transfected MCF-7 cells were detected by Western blot. LKB1 knockdown efficiency was quantified using densitometry. (B) Loss
of LKB1 increased cell migration in wound healing assay. Cell migration into the wound area was photographed at indicated time points, and the
distance between the edges of the lesion was calculated as the migration distance (mm). (C) Loss of LKB1 increased cell invasion in matrigel
transwell chambers. Migrating cells were stained and photographed. Invasion properties were expressed as the number of cells per mm2.
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3D culture
To gain insight into the role of LKB1 in maintenance of
epithelial cell polarity, we performed the 3D morpho-
genesis experiment using either non-targeting siRNA
(NT) or siLKB1(1342/1972) transfected MCF-10A cells
(Figure 7A). When MCF-10A cells were cultured in 3D
reconstituted basement membrane, they reorganized
and differentiated to form acinar structures, character-
ized by apical-basolateral polarization [29,30]. Interest-
ingly, siLKB1 transfected MCF-10A cells formed acini
with abnormally uneven gross morphology. Fifty per-
cent of siLKB1 transfected cells displayed irregular
and rough acinar surfaces, compared to non-targeting
siRNA (NT) transfected cells (Figure 7B). E-cadherin
staining and cis-Golgi matrix protein GM130 staining
[31,32] were conducted to further reveal the morpho-
logical alterations in non-targeting siRNA and siLKB1
acini. Typical features of the siLKB1 acini included un-
even and rough basolateral surface (Figure 7C) andpartial loss of apical polarity due to the localization of
GM130 at the basolateral surface in several MCF-10A
cells (Figure 7D). Altogether, the absence of LKB1 led
to gross abnormality in the acinar structure and partial
loss of cell polarity of the 3D acini.
Discussion
LKB1 is a tumor suppressor gene and loss or mutation
of LKB1 has been detected in various tumors, including
human breast cancer. Patients with PJS, a syndrome
caused by LKB1 germline mutations, have a 54% in-
creased risk of developing breast cancer, compared to
the healthy population [21] and LKB1 is mutated in
30% of sporadic breast cancers [21,33-35]. In the
present study, we detected that LKB1 expression was
negatively correlated with high tumor stage (TNM).
We also reported a statistically significant correlation
between LKB1 expression and ER/PR status. ER/PR
positive tumors showed higher LKB1 expressions than
ER/PR negative tumors, which agrees well with Shen et
Figure 5 LKB1 was localized at adheren junctions and regulated the expressions of EMT markers. (A) MCF-10A was stained for LKB1
(green), E-cadherin (red) and DAPI (blue). (B) Expressions of EMT markers in control and LKB1 overexpressing MDA-MB-435 s. (C) MCF-7 cells
were transfected with non-targeting siRNA (NT) or siLKB1(1342/1972). The protein levels of E-cadherin, N-cadherin and α-SMA were determined
by western blot.
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a co-activator of ERα signaling and enhance ERα trans-
activation via its catalytic activity [36]. Contrary to our
results, Singh et al. showed that LKB1 was repressed
by ERα at the transcriptional level in breast cancer cell
lines [37]. This discrepancy may be due to two reasons:Figure 6 E-cadherin mRNA expression was down-regulated in LKB1 k
siRNA (NT) or siLKB1(1342/1972). The mRNA levels of E-cadherin were dete(1) We used clinical tissue samples to study the correl-
ation between LKB1 and ER, while Singh et al. used
breast cancer cell lines. The mutual regulation of LKB1
and ER may be more complex in tissues than in cell
lines. (2) Other factors or multi-layer mechanisms
may exist for regulating LKB1 and ER expressions innock-down cells. MCF-7 cells were transfected with non-targeting
cted by RT-RCR.
Figure 7 (See legend on next page.)
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Figure 7 Loss of LKB1 resulted in morphological alterations and dysregulation of cell polarity in 3D cultures. (A) MCF-10A cells
were transfected with non-targeting siRNA (NT) or siLKB1(1342/1972). The protein levels of LKB1 were detected by western blot. Efficiency
of knockdown was quantified using densitometry. (B) Morphogenesis of MCF-10A cells plated on matrigel. Phase images of MCF-10A cells
were taken on Day 4 (scale bar, 100 μm). A single acinar structure was taken on Day 8 (scale bar, 100 μm). (C) non-targeting siRNA (NT) or
siLKB1(1342/1972) transfected MCF-10A cells stained with E-cadherin (red) on Day 16. (D) non-targeting siRNA (NT) or siLKB1(1342/1972)
transfected MCF-10A cells stained with GM130 (red, Golgi marker) on Day 12.
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tion of LKB1 and ERα is largely unknown,further
studies are needed to elucidate the mechanism.
Our results showed that LKB1 expression was posi-
tively correlated with HMW-CK expression in clinical
breast cancer tissues. A recent study presented by
Joensuu has shown that HMW-CK5 is significantly re-
duced in metastasis tumor tissues [38]. And alteration
of cytokeratin expression and partial loss of the normal
regulation of cytokeratin expression during carcino-
genesis and tumor progression have been demon-
strated [39]. Together with above studies, our study
indicated that alterations or partial loss of LKB1 and
HMW-CK may occur simultaneously in clinical breast
cancer tissues during tumor progression. To further
demonstrate the positive correlation between LKB1
and HMW-CK, western blot assays were conducted to
determine the expressions of LKB1 and HMW-CK in
breast cancer cell lines. Unexpectedly, HMW-CK was
detected in all cells and showed no difference between
control, LKB1 knockdown and LKB1 overexpressing
cells (Figure 5B and C). The inconsistency between
clinical tumor tissues and cell lines may be that HMW-
CK accumulation needed a longer time than the period
of validity of transient transfection, or may be that
other cells or factors in tumor tissues participated in
regulating HMW-CK expression. The detailed regula-
tory mechanism of HMW-CK expression warrants
further investigation.
LKB1 protein expression levels were highly variable
among different stages of breast cancer and were po-
tentially associated with cancer metastasis and patient
outcome. It has been reported that LKB1 knockdown
increases motility and invasiveness of lung cancer
cells and induces expressions of several mesenchymal
markers and an E-cadherin transcriptional repressor
[25,26]. Sebbagh et al. have found that LKB1 is coloca-
lized with E-cadherin at adherins junctions in Caco-2
and MDCK II cells [24]. In this study, the colocaliza-
tion of endogenous LKB1 and E-cadherin at adheren
junctions was also found in breast epithelial cells. A
significant correlation was detected between LKB1
intensity and E-cadherin in breast cancer tissues. E-
cadherin down-regulation and N-cadherin up-regulation
were detected in LKB1 knock-down cells, which indicatedthat loss of LKB1 expression may induce the EMT
process by promoting the cadherin switch from E-
cadherin to N-cadherin in MCF-7 cells. EMT is a bio-
logic process that allows epithelial cells to lose their
cell polarity and cell-cell adhesion, and to gain migra-
tory and invasive properties [17]. Our results showed
that loss of LKB1 enhanced the migration and invasion
of breast cancer cells. Therefore, LKB1 may play im-
portant roles in migration and invasion of breast can-
cer by regulation of cell polarity.
LKB1 (STK11/Par4/dlkb1), as a master regulator, is
needed for formation of proper epithelial architecture
and cell polarity in mammals [13,40]. LKB1 resides
upstream of the Par protein network. Activation and
translocation of LKB1 by STRAD-MO25 result in
phosphorylation of Par1/MARK1-4. Activated Par1 in
turn phosphorylates Par3, which creates binding sites
for Par5 [41-43]. In our study, MCF-10A epithelial cell
3D culture further proved that LKB1 was necessary
for formation of polarized acinar structures. Loss of
LKB1 led to change in Golgi orientation and abnormal
apico-basal polarity of acinar structures. However, the
molecular mechanisms by which LKB1 regulates cell
polarity in breast cancer remain uncertain. The 3D cul-
ture of MCF-10A epithelial cells offers the possibility
to study the sequential effects of LKB1 on potential
downstream polarity regulators, such as other Par
homologs, Scrib/Lgl/Dlg complex and Crumbs family.Conclusions
Our data indicated that low expression of LKB1 was
significantly associated with established markers of
unfavorable breast cancer prognosis such as loss or
decrease of ER/PR, E-cadherin and HMW-CK expres-
sions. Knockdown of endogenous LKB1 gave rise to
dysregulation of cell polarity and invasive phenotype of
breast cancer cells. Further studies are needed to reveal
the mechanisms underlying the effect of LKB1-induced
cell polarity on breast cancer metastasis and invasion.Abbreviations
LKB1: Liver kinase B1; PJS: Peutz-Jeghers syndrome; AMPK: AMP-activated
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siRNA: Small interfering RNA.
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